According to a statement from the Ministry of Science and Technology, a multi-tiered review process is underway and till date 16 proposals of devices, diagnostics, vaccine candidates, therapeutics and other interventions have been recommended for receiving funding support.
"A multifaceted approach is being adopted to ensure that vaccine candidates utilising different platforms and at different stages of development are fast-tracked through this research consortium under funding from National Biopharma Mission," read the statement.
It added that both, repurposing of existing vaccine candidates for immediate protection of high-risk groups and novel vaccine candidate development were considered while selecting proposals under this call.
"Funding support has been recommended to Cadila Healthcare Ltd for advancing the development of a DNA Vaccine candidate against Novel Coronavirus SARS-CoV-2 and to Bharat Biotech International Ltd for COVID-19 vaccine candidate utilising the inactivated rabies vector platform. Furthermore, for the Phase III human clinical trials study of recombinant BCG vaccine (VPM1002) planned in high-risk population, Serum Institute of India Private Limited (SIIPL) will be supported," the statement read.
The development of a novel vaccine evaluation platform at National Institute of Immunology to support SARS-CoV-2 vaccine development has also been approved for financial support, it added.
Besides this, the production of purified immunoglobulin G, IgG, at commercial scale from COVID-19 convalescent sera and production of high titers of equine hyper immune globulin for the treatment of COVID infected patients on large scale will be supported at Virchow Biotech Pvt Ltd. Financial support to OncoSeek Bio Pvt Ltd will be provided to create an in vitro Lung Organoid model.
Also, to boost indigenous production and to scale-up the production of molecular and rapid diagnostic tests, compes which will receive financial support are Mylab Discovery Solutions Pvt Ltd; Huwel Lifesciences; Ubio Biotechnology Systems Pvt Ltd; Dhiti Life Sciences Pvt Ltd; MagGenome Technologies Pvt Ltd; Bigtec Pvt Ltd; and Yaathum Biotech Pvt Ltd.
"Common shared facility to manufacture diagnostic kits and ventilators will be established at Andhra Pradesh MedTech Zone (AMTZ) under National Biopharma Mission of DBT to provide scale up production capacity to different manufacturers," the statement said.
It added that development and deployment of contactless, affordable thermopile based ultrasonic sensors for screening of COVID-19 suspects and indigenous production of novel PPE for healthcare professionals will also be supported.
( With inputs from ANI )